All Updates

All Updates

icon
Filter
FDA approval
Adicet Bio receives FDA Fast Track Designation for ADI-270 therapy for metastatic/advanced ccRCC
Cell & Gene Therapy
Jul 8, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Jul 11, 2024
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Jul 11, 2024
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Jul 11, 2024
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Jul 11, 2024
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Jul 11, 2024
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Jul 11, 2024
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Jul 11, 2024
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Jul 11, 2024
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Jul 11, 2024
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Jul 11, 2024
Cell & Gene Therapy

Cell & Gene Therapy

Jul 8, 2024

Adicet Bio receives FDA Fast Track Designation for ADI-270 therapy for metastatic/advanced ccRCC

FDA approval

  • Adicet Bio has received Fast Track Designation from the FDA for its therapy candidate, ADI-270. This candidate is aimed at patients suffering from metastatic/advanced clear cell renal cell carcinoma (ccRCC) who have already undergone specific treatments.

  • ADI-270 is an "off-the-shelf" gamma delta CAR T-cell therapy that targets CD70-positive cancers. It is engineered with a third-generation CAR design targeting CD70, using CD27 as the binding factor. It is further strengthened with a dominant negative form of the transforming growth factor-β receptor II (dnTGFβRII), making it a potentially effective treatment for patients with metastatic/advanced ccRCC and other patients with CD70+ tumors.

  • Adicet Bio is a biotechnology company that develops allogeneic gamma delta T-cell therapies for cancer and autoimmune diseases. The company’s approach involves engineering gamma delta T-cells with chimeric antigen receptors (CARs) to create off-the-shelf therapies to provide durable and effective treatments. Its leading product candidate, ADI-001, targets CD20 to treat relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma and autoimmune diseases. Another significant candidate is ADI-270 which targets renal cell carcinoma and other CD70+ solid tumors.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.